TIL Therapy for Solid Tumors

In this episode of ASTCT Talks, host Daniel Olson, MD, of the University of Chicago, is joined by Stephanie Goff, MD, of the National Cancer Institute (NCI), and Allison Betof, MD, PhD, of Stanford Medicine to discuss the evolution and expanding role of tumor-infiltrating lymphocyte (TIL) therapy in solid tumors. From its early development at the NCI to its recent FDA approval in melanoma, the conversation explores how TIL therapy is reshaping treatment options for patients with advanced solid tumors. The discussion highlights:The history and key milestones that led to the development and approval of TIL therapy. The role of TIL therapy in the current melanoma treatment landscape. Practical considerations for treatment delivery, including lymphodepleting chemotherapy and IL-2 administration.This episode provides valuable clinical and operational perspectives on one of the most promising cellular therapy approaches for solid tumors and what’s next for the field.Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going. This episode was made possible through support fromIovance.